Avsola is commonly used to manage moderately to severely active chronic inflammatory conditions when patients have not responded adequately to prior conventional therapies. Its purpose is to provide symptomatic relief and help manage the symptoms related to systemic imbalance that create noticeable physiological strain. The therapeutic role is focused on the management of systemic inflammatory disorders.

The medication is relevant for easing symptomatic discomfort and functional impairment across several major categories, including the inflammatory bowel diseases Crohn’s Disease and Ulcerative Colitis, the inflammatory arthropathies Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis, as well as Chronic Severe Plaque Psoriasis.

“The therapy is relevant for symptom groups involving frequent, distressing manifestations and helps manage symptoms that interfere with daily comfort.”

Crohn’s Disease and Ulcerative Colitis (IBD)

Avsola is applied in the context of persistent, chronic inflammation affecting the digestive tract. The main benefit is supporting management of the symptoms that become more disruptive during flare-ups and assists with maintaining functional stability in the affected area.

---

Quick Fact: Supports easing Joint and Spine Stiffness

Rheumatoid and Psoriatic Arthritis, and Ankylosing Spondylitis

One key therapeutic benefit is that the medication helps manage symptoms that interfere with daily functioning and assists with maintaining functional stability in these arthritic conditions.

Chronic Severe Plaque Psoriasis

The main benefit is assisting with managing symptoms related to inflammatory or irritative states, which contributes to easing the overall symptom load and supports the patient during episodes of heightened discomfort.

Who Can and Cannot Use Avsola (Infliximab)

The eligibility for Avsola is strictly defined by regulatory authorities based on population group and underlying medical conditions.

Classification	Population/Condition
Contraindicated	Patients with a prior severe hypersensitivity reaction to infliximab, its excipients, or any murine proteins
Contraindicated	Patients with moderate or severe congestive heart failure (NYHA Class III/IV) at doses greater than 5 mg/kg
Prohibited	Patients with active severe infections, including Tuberculosis (TB) or sepsis

Age-Related Eligibility: Avsola is approved for adults across all indications. For pediatric patients, use is established for Crohn's Disease and Ulcerative Colitis in those 6 years of age and older. Safety and effectiveness are not established in children under 6. The risk of serious infections may be higher in patients 65 years and older.

Conditional Use and Restrictions: Use is not recommended during pregnancy or lactation unless clearly necessary. Patients with latent TB must initiate treatment for the infection prior to starting Avsola. Caution is advised for chronic carriers of Hepatitis B Virus and individuals with a history of malignancy or demyelinating diseases.

Avsola (infliximab-axxq) is a biologic medicine that affects the immune system, and its use requires careful consideration of interactions with other medicines and products.

Contraindicated and Not Recommended Combinations

To avoid a heightened risk of serious infections, concurrent use of Avsola is not recommended or is contraindicated with several classes of medicine:

• Other Biologic Products: Combination with other biologic disease-modifying antirheumatic drugs (DMARDs) used to treat the same conditions, such as anakinra or abatacept, is not recommended due to increased infection risk without demonstrated added clinical benefit.
• Live Vaccines/Therapeutic Infectious Agents: Administration of live vaccines is contraindicated during Avsola treatment. A waiting period of at least six months is recommended before giving live vaccines to infants exposed to Avsola in utero.

Combinations Requiring Caution

• Immunosuppressants: Concomitant use with other immunosuppressive agents like azathioprine (AZA) or 6-mercaptopurine (6-MP) may increase the risk of serious complications, including infections and a rare, fatal type of cancer (hepatosplenic T-cell lymphoma), especially in young male patients with inflammatory bowel disease.
• CYP450 Substrates: By reducing the activity of TNF- alpha, Avsola may normalize levels of certain liver enzymes, called cytochrome P450 (CYP450) enzymes. This can change the plasma concentrations of other medicines that are broken down by these enzymes, necessitating monitoring for potential changes in effect or dose adjustments.

Avsola should not be infused concomitantly in the same intravenous line with any other agents.

Targeted Mechanism of Action: TNF- alpha Neutralization

Avsola (Infliximab) functions as a chimeric monoclonal antibody that exerts its activity through the selective binding and neutralization of Tumor Necrosis Factor-alpha (TNF- alpha). The drug binds with high affinity to both the soluble (circulating) and transmembrane (cell-surface bound) forms of this cytokine. By sequestering TNF- alpha, Avsola prevents it from binding to its cognate receptors (TNFRs), thereby interrupting the upstream signaling cascade that facilitates sustained inflammatory responses.

Beyond simple neutralization, the drug’s binding to transmembrane TNF- alpha on activated immune cells (e.g., macrophages) triggers Fc-mediated functions. These include the initiation of apoptosis (programmed cell death) and Antibody-Dependent Cell-mediated Cytotoxicity (ADCC), which acts to reduce the number of TNF- alpha-expressing immune cells within the system. This combined molecular and cellular mechanism results in a suppression of systemic inflammatory mediator release and a subsequent downregulation of the chronic inflammatory state.

Efficacy is influenced by the potential development of anti-drug antibodies (ADAs). Co-administration of immunosuppressants is a secondary mechanism that suppresses ADA formation, thereby maintaining Avsola’s functional concentration and continuous TNF- alpha neutralization in the system.

How Avsola is Used in Clinical Practice

Avsola (infliximab-axxq) is administered exclusively as an intravenous (IV) infusion under the supervision of a qualified healthcare professional in a clinical setting. The medicine is supplied as a lyophilized powder in 100 mg vials, requiring specific preparation prior to delivery.

---

Dosing and Schedule Principles

Avsola dosing is based on body weight (mg/kg) for all approved conditions and follows a two-phase regimen:

1. Induction Phase: A starter schedule of three doses is administered at Week 0, Week 2, and Week 6 across all indications, including Crohn’s Disease, Ulcerative Colitis, and the various forms of arthritis.
2. Maintenance Phase: Following induction, the medication is given at fixed intervals, typically every 8 weeks. For Ankylosing Spondylitis, the maintenance frequency is every 6 weeks.

For most adult indications, including Psoriatic Arthritis and Plaque Psoriasis, the standard dose is 5 mg/kg. For patients with Crohn's Disease or Ulcerative Colitis who do not show a response by Week 14, treatment may be discontinued, as continued use is unlikely to be beneficial.

---

Administration Requirements

Administration involves strict procedural constraints. The powder must be reconstituted and then diluted using only sterile 0.9% Sodium Chloride Injection. The resulting infusion must be delivered over a period of not less than 2 hours and must be administered within 3 hours of preparation. Special in-line filters are mandatory for the infusion set. For Rheumatoid Arthritis, Avsola must be administered in combination with methotrexate.

Avsola: Summary of Clinical Evidence

Avsola (infliximab-axxq) is a biosimilar product to the reference infliximab. Its approval was based on a comprehensive evaluation known as the "totality of evidence," which aimed to establish that the product is highly similar to the reference product with no clinically meaningful differences in terms of safety, purity, and potency.

Biosimilarity Studies

The stepwise approach for approval included analytical, functional, pharmacokinetic (PK), and clinical data comparisons. Analytical testing confirmed that Avsola is structurally and functionally similar to the reference product. A key component of the clinical development program involved a randomized, double-blind study focused on patients with moderately to severely active rheumatoid arthritis (RA).

• Primary Endpoint: The study evaluated the percentage of patients achieving an American College of Rheumatology 20% improvement criteria (ACR20) response at Week 22. The results of this study suggested comparable response rates between Avsola and the reference product.
• Switching Data: The trial also included a subgroup of patients who transitioned from the reference product to Avsola at Week 22. Safety and immunogenicity profiles observed in patients who switched treatments were noted to be similar to those continuously receiving the reference product or Avsola.

Extrapolated Indications

Based on the totality of evidence, including the clinical data in RA patients, regulatory bodies determined that the findings could be extrapolated to all other approved indications of the reference product. These indications relate to the management of several chronic inflammatory conditions in adults and children (age 6 and older), which may include:

• Crohn's Disease
• Ulcerative Colitis
• Psoriatic Arthritis
• Ankylosing Spondylitis
• Plaque Psoriasis

Safety Considerations from Clinical Data

Clinical trial and post-marketing data from infliximab products emphasize important safety information. A heightened risk of serious infections, including tuberculosis and invasive fungal infections, has been observed in patients treated with TNF blockers. Lymphoma and other malignancies, some of which were fatal, have also been reported in pediatric and adult patients receiving this class of medication.

Common questions about Avsola (FAQ)

Q: Is Avsola the same type of medicine as Remicade or Inflectra?

A: Avsola is classified as a biosimilar to the reference product, Remicade (infliximab). This classification means that it has been rigorously evaluated and determined to be highly similar to Remicade, with no clinically meaningful differences in terms of safety or effectiveness. Inflectra is also a biosimilar version of the same active ingredient.

Q: How quickly does Avsola start working after the first infusion?

A: Studies and official information indicate that treatment response varies among individuals and conditions. For certain inflammatory bowel diseases, regulatory documents mention that if a patient has not shown a response by Week 14 of treatment, continuing the medication is unlikely to be beneficial. This 14-week period is often used as a clinical checkpoint to evaluate efficacy.

Q: Can Avsola be used to treat uveitis?

A: The official product information lists the approved uses of Avsola, which include several types of arthritis, Crohn’s Disease, Ulcerative Colitis, and Plaque Psoriasis. At this time, uveitis is not listed as an approved indication for Avsola.

Q: What kind of monitoring tests are needed while on Avsola?

A: Official guidelines state that patients must be screened for latent tuberculosis (TB) and Hepatitis B Virus (HBV) before starting treatment. Regulatory documents indicate that ongoing monitoring is important. For instance, because elevated liver enzymes have been reported as a common side effect, monitoring of liver function tests is often part of the prescribed treatment plan.

Q: Does Avsola interact with common pain relievers like Tylenol or Advil?

A: The official label focuses on interactions with other biologics, vaccines, and certain prescription immunosuppressants. It does not specifically name common over-the-counter pain relievers like acetaminophen (Tylenol) or ibuprofen (Advil). As Avsola can affect certain liver enzymes, patients are generally advised to inform their healthcare provider about all medicines taken.

Q: Can Avsola cause weight gain or weight loss?

A: Weight change is not typically listed as a common side effect of Avsola. However, unexplained weight loss can be a symptom associated with serious concerns like infection or malignancy. Additionally, rapid weight gain along with swelling can be a sign of new or worsening heart failure. These symptoms are important safety information and are typically included in the list of events that patients should be aware of.

Q: Is Avsola used for conditions outside of arthritis and gut issues?

A: Yes. While Avsola is approved for inflammatory bowel diseases (Crohn's Disease and Ulcerative Colitis) and forms of arthritis, it is also approved for the treatment of the chronic skin condition Plaque Psoriasis.

Q: Are infusion-related reactions always serious when receiving Avsola?

A: No. Infusion reactions are categorized as a Very Common side effect, meaning they occur frequently in studies. While severe reactions like anaphylaxis are possible, most infusion reactions are not severe. These usually happen during the infusion or within two hours of its completion and can include symptoms like headache, fatigue, or flushing.

Q: Can Avsola treatment affect fertility?

A: Official information indicates that it is not known if Avsola makes it harder for women to get pregnant. For men, though some laboratory studies have shown changes in sperm, clinical evidence has not found a clear link to long-term fertility issues.

Q: What is the difference between Avsola and taking a steroid medication?

A: Avsola is a specific type of biologic medicine called a TNF-alpha blocker, which targets a single key inflammatory protein. Steroid medications (corticosteroids) are a broader class of anti-inflammatory drugs that affect the body's immune system in many ways. In some cases, official treatment goals for Avsola include reducing or eliminating the long-term need for steroids.

Q: Does Avsola interact with oral contraceptives?

A: The official label does not specifically name oral contraceptives. However, Avsola may change the activity of certain liver enzymes that break down other medications. Clinical practice generally involves monitoring for potential changes in effect when a patient is taking multiple medications.

Q: Can I still take my regular vitamins and supplements while on Avsola?

A: Patient information sheets often state the importance of notifying the prescribing physician about all medications, vitamins, supplements, and herbal remedies being used. While there are no specific known interactions between Avsola and most standard vitamins, providing a full list allows the healthcare provider to check for any potential conflicts.

Q: Does Avsola impact blood pressure or cholesterol levels?

A: Changes in blood pressure or heart rhythm may occur during the infusion itself, requiring monitoring by the healthcare professional. For blood cholesterol, clinical research has generally shown no significant change in overall serum lipid levels over several months of treatment.

Q: What counts as a 'serious infection' when mentioned in Avsola warnings?

A: A serious infection, as defined in regulatory warnings, is one that may lead to hospitalization or be life-threatening. Specific examples highlighted in the official product information include the reactivation of latent tuberculosis (TB) and severe fungal infections like histoplasmosis.

Q: What are the components (ingredients) of Avsola?

A: The main active ingredient is infliximab-axxq. Avsola is a large protein, classified as a biologic medicine. While the full list of inactive ingredients (excipients) is highly technical, official warnings state that the drug is contraindicated if a patient has a known hypersensitivity to the excipients or to any murine proteins.

Q: Does Avsola have a Black Box Warning?

A: Yes. Avsola has a Boxed Warning (also commonly known as a 'Black Box Warning') mandated by the FDA. This warning highlights the most serious risks associated with the medication, specifically the risk of developing serious infections (including TB) and the risk of malignancy (cancers, including lymphoma).

Q: Is Avsola a type of chemotherapy?

A: No. Avsola is a Tumor Necrosis Factor (TNF-alpha) blocker and an immunosuppressant. It is a biologic medicine that works by interrupting specific inflammatory pathways. This is distinct from chemotherapy drugs, which generally work by targeting and killing rapidly dividing cells.

Q: What is the half-life of Avsola in the body?

A: Official clinical pharmacology data indicates that the elimination half-life of Avsola is approximately 7 to 12 days. This represents the time it takes for half of the medicine to be cleared from the bloodstream, which supports its extended dosing schedule of several weeks.

Q: How many years of research evidence back Avsola?

A: The active ingredient in Avsola, infliximab, has been in use for a long time. The original reference product was first approved by the FDA in 1998. Therefore, the clinical experience and safety data related to this class of medication span over two decades.

How to Store and Dispose of Avsola

The storage and handling of Avsola (infliximab-axxq) must strictly follow the conditions specified in the government-approved labeling.

Official Storage Requirements

Condition	Requirement
Temperature	Store unopened vials refrigerated between 2°C to 8°C (36°F to 46°F).
Light Protection	Keep vials in the original carton to protect them from light.
Prohibited	The product must not be frozen and cannot be returned to the refrigerator after being stored at room temperature (up to 30°C) for up to six months.
Prepared Solution	Avsola is preservative-free; do not store any unused portion of the reconstituted solution or the final infusion solution.

Disposal and Safety

All vials and waste materials must be kept out of the sight and reach of children.

Disposal of unused or expired product must be carried out in accordance with local regulatory guidelines for pharmaceutical waste and must not be placed in household trash or down the drain unless specifically authorized.